Folate Conjugated Doxorubicin-Loaded Membrane Vesicles for Improved Cancer Therapy

Mishra, Pinki; Jain, Neeraj

doi:10.1080/714044320

Cited by 8 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, sustained release has been observed for drugs that were encapsulated in polymeric core nanoparticles and sequentially coated with cell membranes. In one study, RBC vesicles were found to release more than 50% of encapsulated doxorubicin in the first 16 h 52 . However, the encapsulation of doxorubicin in a PLGA core and subsequent RBC membrane coating was shown to delay the release, with 50% release seen at 36 h 53 .…”

Section: Technologies For Engineering Cell Membrane-derived Vesiclesmentioning

confidence: 99%

Cell membrane-derived vesicles for delivery of therapeutic agents

Lee

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Cell membranes have recently emerged as a new source of materials for molecular delivery systems. Cell membranes have been extruded or sonicated to make nanoscale vesicles. Unlike synthetic lipid or polymeric nanoparticles, cell membrane-derived vesicles have a unique multicomponent feature, comprising lipids, proteins, and carbohydrates. Because cell membrane-derived vesicles contain the intrinsic functionalities and signaling networks of their parent cells, they can overcome various obstacles encountered in vivo . Moreover, the different natural combinations of membranes from various cell sources expand the range of cell membrane-derived vesicles, creating an entirely new category of drug-delivery systems. Cell membrane-derived vesicles can carry therapeutic agents within their interior or can coat the surfaces of drug-loaded core nanoparticles. Cell membranes typically come from single cell sources, including red blood cells, platelets, immune cells, stem cells, and cancer cells. However, recent studies have reported hybrid sources from two different types of cells. This review will summarize approaches for manufacturing cell membrane-derived vesicles and treatment applications of various types of cell membrane-derived drug-delivery systems, and discuss challenges and future directions.

show abstract

Section: Technologies For Engineering Cell Membrane-derived Vesiclesmentioning

confidence: 99%

Cell membrane-derived vesicles for delivery of therapeutic agents

Lee

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

“…Drugs encapsulated in polymeric core nanoparticles that have been successively coated with cell membranes have been shown to have a prolonged release after being injected. One investigation discovered that RBC vesicles released more than 50% of the encapsulated doxorubicin in the first 16 hours [72] after being implanted. Doxorubicin was encapsulated in a polylactic acid core and then coated with an RBC membrane, which was demonstrated to delay the release, with 50 percent release observed after 36 hours [73].…”

Section: Extraction Of Cell Membrane and Formation Of Nano Vesiclesmentioning

confidence: 99%

"Cell Membrane Nano Vesicles as Drug Carriers: Biomedical Applications"

Islam

2022

BJSTR

View full text Add to dashboard Cite

Cell therapy replaces damaged tissue or cells with intact and living cells obtained from the patient (autologous cells) or a donor (allogeneic cells). Cell therapy may have its origins in 1931 when Swiss physician Paul Niehans attempted to cure a patient by injecting calf embryos. Various cell types have been engineered as novel therapeutics for multiple diseases and conditions due to evolving research and emerging innovative technologies [1-3]. Cells such as erythrocytes, platelets, cancer cells, leukocytes, stem cells, and bacteria may be used. Among these, erythrocytes have a high degree of biocompatibility when used as autologous cells or carriers of therapeutic agents [4,5]. Platelets have been extensively studied as novel drug delivery carriers for enhanced efficacy due to their critical roles in hemostasis and thrombosis and their newly discovered role in the development and metastasis of tumors [6,7]. Synthetic nanoparticles (NPs) have been used to diagnose and deliver drugs to patients suffering from various diseases [8-15]. NPS are synthesized from a variety of materials, including lipids [16,17], polymers [18], proteins [19-22], and metals [23-25]. NPS are frequently conjugated with targeting ligands or antibodies to deliver them to pathological sites in the body [26]. However, the biofunctionalization of NPs is insufficient to replicate the complex and multicellular interactions found in the human body, potentially limiting the efficacy of drug delivery via those nanotechnologies [27,28]. Intercellular communication is critical for survival and homeostasis maintenance in all multicellular systems.

show abstract

“…Folic acid (FA) is a water-soluble vitamin B which is generally recognized as an effective tumor-targeting agent to conjugate with nanoparticles (Mishra & Jain, 2003;Bhattacharya et al, 2007;Zhang et al, 2010;Lee et al, 2013;Li et al, 2013). FA receptors exhibit limited expression on healthy cells but are often present in large numbers on cancer cells (Kamen & Capdevila, 1986).…”

Section: Introductionmentioning

confidence: 99%

Folic acid-conjugated superparamagnetic iron oxide nanoparticles for tumor-targeting MR imaging

Gao²,

Jiang

et al. 2015

Drug Delivery

View full text Add to dashboard Cite

Superparamagnetic iron oxide nanoparticles (SPIONs) have been the subject of extensive research due to their potential biomedical applications. In the present investigation, superparamagnetic FA-PEI-Fe 3 O 4 were successfully prepared and evaluated as a targeted MRI contrast agent. FTIR characteristics, TGA, VSM, and MR imaging confirmed the composition and magnetic properties of the synthesized nanoparticles. TEM showed that FA-PEI-Fe 3 O 4 were spherical in shape and well dispersed. The nanoparticles were superparamagnetic at room temperature with a saturation magnetization value of 67.1 emu/g. The nanoparticles showed higher uptake efficiency due to receptor-mediated endocytosis. Moreover, specificity of FA-PEI-Fe 3 O 4 to target tumor cells was demonstrated by the increased nanoparticle uptake and significant contrast enhancement of KB cells over MCF7 cells. The competitive inhibition of FA-PEI-Fe 3 O 4 by free FA further confirmed the specific interaction of this conjugate with FA receptors. In vivo MR imaging studies showed a decreased signal intensity and enhanced tumor contrast post-injection of FA-PEI-Fe 3 O 4 . These results indicate that FA-PEI-Fe 3 O 4 can be used as a promising tumor-targeting agent as well as a T 2 negative-contrast agent in MR imaging applications.

show abstract

Folate Conjugated Doxorubicin-Loaded Membrane Vesicles for Improved Cancer Therapy

Cited by 8 publications

References 0 publications

Cell membrane-derived vesicles for delivery of therapeutic agents

Cell membrane-derived vesicles for delivery of therapeutic agents

"Cell Membrane Nano Vesicles as Drug Carriers: Biomedical Applications"

Folic acid-conjugated superparamagnetic iron oxide nanoparticles for tumor-targeting MR imaging

Contact Info

Product

Resources

About